Shares of Aptorum Group Limited (NASDAQ:APM – Get Free Report) were down 4.6% on Thursday . The company traded as low as $0.60 and last traded at $0.6680. 167,078 shares changed hands during mid-day trading, an increase of 188% from the average session volume of 57,956 shares. The stock had previously closed at $0.70.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded Aptorum Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.
View Our Latest Analysis on APM
Aptorum Group Stock Performance
Aptorum Group Company Profile
Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.
The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.
Further Reading
- Five stocks we like better than Aptorum Group
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
- Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
- MarketBeat Week in Review – 08/03 – 08/07
Receive News & Ratings for Aptorum Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptorum Group and related companies with MarketBeat.com's FREE daily email newsletter.
